- Home
- FTW vs ZVRA Comparison
FTW vs ZVRA Comparison
Compare FTW & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$11.03
Company Overview
Basic Information| Metric | FTW | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 472.9M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FTW | ZVRA |
|---|---|---|
| Price | $12.10 | $11.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 87.9K | ★ 553.2K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $9.50 | $6.19 |
| 52 Week High | $17.20 | $13.16 |
Technical Indicators
Market Signals| Indicator | FTW | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 78.08 |
| Support Level | N/A | $8.31 |
| Resistance Level | N/A | $12.14 |
| Average True Range (ATR) | 1.79 | 0.39 |
| MACD | 0.16 | 0.15 |
| Stochastic Oscillator | 32.47 | 94.95 |
Price Performance
Historical Comparison FTW
ZVRA
About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
EQV Ventures Acquisition Corp is a blank check company.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.